Secondary hyperparathyroidism

New Clinical Data on OPKO Health’s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

Retrieved on: 
Donnerstag, November 2, 2023
EGFR, Secondary hyperparathyroidism, SHPT, ERC, Health, Glomerular filtration rate, HIV disease progression rates, Society, American Society of Nephrology, Phosphorus, Chronic kidney disease, Dialysis, Parathyroid hormone, ASN, Serum, OPKO Health, CKD, Patient, Calcium, Pharmaceutical industry

MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) presented late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia today.

Key Points: 
  • MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) presented late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia today.
  • Treatment with RAYALDEE was not associated with clinically meaningful increases in serum calcium or phosphorus.
  • “RAYALDEE is a safe and highly effective treatment for SHPT in patients with stage 3 or 4 CKD.
  • The new data presented today clearly highlight the possibility that raising serum 25-hydroxyvitamin D to a sufficiently high level to achieve consistent iPTH control with RAYALDEE would improve outcomes in CKD patients.”

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

Retrieved on: 
Mittwoch, Oktober 25, 2023
Real-World Evidence, FASN, Secondary hyperparathyroidism, Importance, ERC, Health, Poster, Society, American Society of Nephrology, ASN, Calcitriol, Serum, Quality, OPKO Health, CKD, FACP, Paricalcitol, Patient, Calcifediol, Pharmaceutical industry, SHPT

MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia on Thursday, November 2, 2023.

Key Points: 
  • MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia on Thursday, November 2, 2023.
  • OPKO Health will present two other posters at ASN Kidney Week summarizing additional new clinical data on RAYALDEE.
  • The data demonstrate that effective control of SHPT has been achieved with RAYALDEE treatment in both randomized clinical trials and in a real-world clinical experience trial.
  • Data from these trials support early initiation of SHPT treatment with RAYALDEE in order to delay disease progression.

Ardelyx Reports Additional Positive Data Supporting Clinical Utility of Tenapanor at ASN's Kidney Week 2021

Retrieved on: 
Freitag, November 5, 2021
Control, Society, MPH, LVH, PTH, Therapy, Calcium, Clinical trial, Constipation, Serum, ESRD, Magnesium, Mortality, Safety, HD, Left ventricular hypertrophy, Knight Therapeutics, Kidney, BID, Method, NHE3, Phosphorus, Blood, Nephrology, FDA, Metabolic acidosis, Adult, Quality of life, FGF23, View, Potassium, CKD, PD, Health, Multimedia, Chronic kidney disease, Hyperphosphatemia, Sodium, Hyperkalemia, Renal Association, PAI, Dialysis, Cohort, Kyowa Hakko Kirin, Electrolyte, Diarrhea, Kidney disease, Parathyroid hormone, Human, Defecation, Fosun Pharma, Serum albumin, ASN, IBS-C, Secondary hyperparathyroidism, Pharmaceutical industry

Ardelyx has completed three successful Phase 3 pivotal trials, and an additional clinical trial (OPTIMIZE) for tenapanor, an investigational, first-in-class phosphate absorption inhibitor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

Key Points: 
  • Ardelyx has completed three successful Phase 3 pivotal trials, and an additional clinical trial (OPTIMIZE) for tenapanor, an investigational, first-in-class phosphate absorption inhibitor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
  • "These data provide additional perspective on the potential benefits of tenapanor and further support its utility in the management of serum phosphorus," said Laura Williams, M.D., MPH, chief medical officer for Ardelyx.
  • Tenapanor has the potential to help more patients achieve target phosphorus levels and reduce the treatment burden associated with currently available hyperphosphatemia therapies.
  • The incorporation of the patient voice into the clinical trial design and evaluation of tenapanor is a huge step forward for patients."

OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor

Retrieved on: 
Montag, Mai 24, 2021
Bad Homburg vor der Höhe, Secosteroids, Vitamin D, Vifor Pharma, Companies, OPKO Health, Fresenius, Germany, Calcifediol, Calcitriol, Secondary hyperparathyroidism, Health care

MIAMI, May 24, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco Inc. (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP).

Key Points: 
  • MIAMI, May 24, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco Inc. (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP).
  • RAYALDEE is an extended release formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3.
  • RAYALDEE is approved to treat SHPT in adults with stage 3 or 4 CKD and vitamin D insufficiency in the U.S. and 11 European countries.
  • Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care) is part of the Vifor Pharma Group (VPG), a global pharmaceutical company.

Global Secondary Hyperparathyroidism Pipeline Insights, 2020 - ResearchAndMarkets.com

Retrieved on: 
Dienstag, August 4, 2020
Health, Clinical trials, RTT, Secondary hyperparathyroidism, Hyperparathyroidism, Pipeline, Drug pipeline

The "Secondary Hyperparathyroidism Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Secondary Hyperparathyroidism Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
  • Global Secondary Hyperparathyroidism market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates.
  • This Secondary Hyperparathyroidism pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
  • The competitive intelligence report on Secondary Hyperparathyroidism presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Secondary Hyperparathyroidism pipeline.

Pipeline Review on Secondary Hyperparathyroidism - H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, Februar 27, 2020
Professional services, Consulting, Hormones, Glands, Organ systems, Secondary hyperparathyroidism, Hyperparathyroidism, Parathyroid hormone

The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

Key Points: 
  • The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide reviews key companies involved in Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • Formulate corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.

Secondary Hyperparathyroidism Pipeline Review, H1 2019 Report - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, August 8, 2019
Health, Pharmaceutical, Animal anatomy, Anatomy, Hyperparathyroidism, RTT, Secondary hyperparathyroidism, Parathyroid gland, Human anatomy

The "Secondary Hyperparathyroidism - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Secondary Hyperparathyroidism - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Secondary Hyperparathyroidism - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

Rockwell Medical Schedules Third Quarter 2018 Conference Call

Retrieved on: 
Montag, Oktober 29, 2018
Medicine, Anatomy, RTT, Kidney diseases, Rockwell Medical, Clinical medicine, Organ failure, Nephrology, Secondary hyperparathyroidism, Membrane technology, Chronic kidney disease, Hyperparathyroidism

Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD).

Key Points: 
  • Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD).
  • Rockwell Medical's anemia drug Triferic is the only FDA-approved product indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients.
  • Rockwell's FDA approved generic drug Calcitriol (active vitamin D) is for treating secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
  • Rockwell expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Rockwell Medical Provides Investor Update

Retrieved on: 
Montag, Juli 2, 2018
Medicine, Clinical medicine, Anatomy, Membrane technology, RTT, Rockwell Medical, Kidney diseases, Renal dialysis, Nephrology, Hemodialysis, Chronic kidney disease, Secondary hyperparathyroidism

Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.

Key Points: 
  • Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.
  • Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market and other major markets globally.
  • Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis.
  • Rockwell expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.